Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BMS-663068 in Renal Impairment
NCT02674581Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Feb 2016
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fostemsavir in human immunodeficiency virus infection (HIV) (5 arms), sponsored by ViiV Healthcare. Primary endpoint: Effect of Renal Impairment on The Primary Endpoints of Cmax. Started Feb 2016; status: completed.
02
Drugs
fostemsavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02674581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02674581.